American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...
SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...
External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...
In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...
Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.
PORTOS can determine which patients with localized prostate cancer will benefit from dose-escalation of radiotherapy, data suggest.
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback